Sam S. Chang, MD

Patricia and Rodes Hart Chair of Urologic Surgery
Vanderbilt University Medical Center

Sam S. Chang, MD, MBA, Patricia and Rodes Hart Endowed Professor of Urologic Surgery and Oncology, is the Oncology Fellowship Director and Vice-Chair of Urologic Surgery at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Chang, a graduate of Princeton University and Vanderbilt University Medical School, completed his uro-oncology fellowship as Chief Fellow at Memorial Sloan-Kettering Cancer Center. He has also recently completed his MBA at Vanderbilt’s Owen School of Business.
Dr. Chang has served as the Chairman of the SUO Panel on Hormone Refractory Prostate Cancer, the chair of the American Joint Committee on Cancer GU Staging Task Force, the Facilitator and Vice-Chair of the Renal Malignancy Follow-Up AUA Guidelines Panel, the Chair of the AUA/ASCO/ASTRO/SUO Guidelines on Nonmetastic Invasive Bladder Cancer and AUA/SUO Guidelines on Nonmuscle invasive Bladder Cancer, and the Chairman of the AUA Prostate Cancer Core Curriculum Committee. He is a current member of the NCCN Kidney Cancer Panel and is a Senior Editor of the American Board of Urology Examination committee. In addition, he was named an AUA-EAU Academic Exchange Fellow. While maintaining a busy clinical surgical practice, Dr. Chang has authored more than 275 original publications, multiple book chapters and edited several textbooks. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, a CaPCURE Young Investigator Award, and has been named multiple times as a Journal of Urology’s Best Reviewer. Dr. Chang was named as the 2011 recipient of the American Urologic Association Gold Cystoscope Award and completed a term as a nominated Fellow of the Nashville Health Care Council in 2016. He has been elected (2018-2022) as Assistant Secretary of the American Urological Associationt.

Presentation(s):

• PD15 - PD15: Prostate Cancer: Advanced (including Drug Therapy) I

  Friday, May 3
  1:00 PM – 3:00 PM

• 038IC: Case-Based Discussion of AUA Non-muscle Invasive Bladder Cancer Guidelines

  Saturday, May 4
  1:30 PM – 3:30 PM

• AUA Bladder Cancer Guidelines: Highlights and Key Points

  Saturday, May 4
  4:30 PM – 4:45 PM

• Closing Remarks

  Saturday, May 4
  4:45 PM – 5:00 PM

• Lecture 2: Key Points of the AUA Guidelines for Invasive Cancer

  Sunday, May 5
  2:15 PM – 2:30 PM

• Panel Discussion on Clinical Cases: What is your Choice of Treatment?

  Sunday, May 5
  2:30 PM – 3:00 PM

• LBA-18: Late-Breaking Abstract: Preliminary Phase 2 Clinical Results of IL-15RαFc Superagonist N-803 with BCG in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Patients Demonstrates 82% CR of Carcinoma in situ (CIS)

  Sunday, May 5
  3:35 PM – 3:44 PM